Skip to content
Business Company News, Finance Investment

LTR Pharma Wins IPO of the Year Award, Celebrating Groundbreaking Advancements in Men’s Health

Jane Morgan Management 2 mins read

Sydney, Australia – 14 June 2024 – LTR Pharma, an ASX-listed company dedicated to improving men's health, is proud to announce be announced as the winner of the prestigious IPO of the Year Award. This accolade highlights the company's remarkable entry into the public market and its promising future in the healthcare sector. The Australian Stockbrokers Foundation award ceremony was held last night at the Sofitel Wentworth in Sydney and celebrated LTR Pharma's innovation and impact.


Alpine Capital has been instrumental in this achievement, acting as the Lead Manager for LTR Pharma's successful IPO. Their expertise and strategic guidance have played a crucial role in navigating the complexities of the public listing process and positioning LTR Pharma for ongoing success.


Since IPO, LTR Pharma stock has traded up 300% above its listing price of 20c following the announcement of the announcement of the exceptional initial SPONTAN results, with full trial results anticipated in the coming months.


LTR Pharma's primary focus is on enhancing men's physical and mental health through the commercialisation of their groundbreaking nasal spray treatment for Erectile Dysfunction (ED). ED is a significant health issue affecting millions of men worldwide, often leading to diminished self-esteem and strained relationships. LTR Pharma's lead product, SPONTAN, offers a unique solution with its innovative mechanism of action.


SPONTAN distinguishes itself from existing ED therapies through its intranasal delivery technology of a PDE5 inhibitor. The nasal cavity, being a highly vascular part of the body, facilitates rapid and even absorption of the drug, allowing it to take effect within 10 minutes or less. This swift action empowers men to regain control over the timing, spontaneity, and enjoyment of their sexual experiences, making SPONTAN a revolutionary advancement in ED treatment.

Phil Cawood, co-founder of Alpine Capital, expressed his enthusiasm: "Working with LTR Pharma on their IPO has been a rewarding experience. Their commitment to innovation in men's health is truly inspiring, and we are proud to have played a role in their successful market entry. This recognition is well-deserved, and we anticipate a bright future for the Company."


Contact details:

For further information 

Jane Morgan

More from this category

  • Business Company News, Food Beverages
  • 19/07/2024
  • 12:50
Brisbane Convention & Exhibition Centre (BCEC)

Seasoned by Queensland – this is how to feed our visitors!

Local Produce the Standout at Brisbane Convention & Exhibition Centre MENU LAUNCH Brisbane Convention & Exhibition Centre (BCEC) has launched its 2024 Menu, Seasoned…

  • Contains:
  • Business Company News, Indigenous
  • 18/07/2024
  • 16:07
Parliament of Australia

Melbourne hearing for inquiry into improving the economic self-determination for First Nations Australians

The Joint Standing Committee on Aboriginal and Torres Strait Islander Affairs will hold a public hearing in Melbourne on 19 July for the inquiry into improving the economic prosperity for First Nations Australians. The Committee is looking forward to hearing firsthand from Victoria’s Aboriginal and Torres Strait Islander organisations at the forefront of business enterprise, about the barriers to and opportunities for economic development for First Nations people. The Committee will discuss the latest research from the Dilin Duwa – Centre for Indigenous Business Leadership and the University of Melbourne about the enormous contribution of Indigenous businesses to the Australian…

  • Business Company News, Oil Mining Resources
  • 18/07/2024
  • 11:04
Jane Morgan Management

Resouro Strategic Metals Inc. (ASX:RAU) Announces Maiden JORC Resource for the Tiros Project

Sydney, Australia, 18 July 2024 | Resouro Strategic Metals Inc. (ASX:RAU; TSX-V:RSM; FSE:BU9; OTC:RSGOGF) is pleased to announce the publication of its maiden JORC-compliant Mineral Resource Estimate (“MRE”) for the Tiros Titanium and Rare Earth Elements Project in Brazil (“Tiros Project” or “Tiros” or “Project”). This marks a significant milestone in the Project’s development. Highlights Maiden JORC MRE: The Tiros Project boasts 1.7 billion tonnes (bn tonnes) at 3,900 parts per million (“ppm”) Total Rare Earth Oxide (“TREO”), 1,100 ppm Magnet Rare Earth Oxides (“MREO”), and 12% Titanium Dioxide (“TiO2”) in all three resource categories. High Grade Domain: Within the…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.